PMC

Vitamin D level distribution over 1 year among the schizophreniform and autism spectrum disorder groups. Five patients reached recommended levels >30 ng/ml: patient 1: 43 years, female, schizophreniform syndrome (organic schizophreniform disorder), treated with olanzapine, body mass index (BMI) of 26.7 kg/m²; patient 2: 25 years, male, autism spectrum disorder (Asperger syndrome), no psychiatric medication, BMI of 19.4 kg/m²; patient 3: 41 years, male, autism spectrum disorder (atypical autism), treated with olanzapine and clomipramine, BMI of 23.7 kg/m²; patient 4: 37 years, male, schizophreniform syndrome (schizophrenia), treated with olanzapine and escitalopram, BMI of 25.6 kg/m²; patient 5: 21 years, male, schizophreniform syndrome (schizoaffective disorder), treated with quetiapine and venlafaxine, BMI of 26.4 kg/m².

Forest plot of the prevalence of schizophreniform disorders among homeless people. The figure shows the results of the meta-analysis of the studies on schizophreniform disorders on homeless

Individual relational memory performance in the schizophreniform disorder and schizophrenia groups. (A) Face-scene binding (FSB) performance was heterogeneous in both patient groups. (B) The majority of schizophreniform disorder participants showed good associative inference (AI) performance, while the schizophrenia group was more heterogeneous.

Percentage of drug used by the schizophreniform patients.